A small AI funding round landed that will not trend on any front page, and that is exactly why I want to talk about it.
Faro, a San Diego startup, raised 37.3 million dollars in a Series B led by Merck’s Global Health Innovation Fund and S32. Not a huge number by AI standards these days, people talk in billions now. But the company behind it is already used by six of the ten biggest pharmaceutical companies in the world, and what it does is worth a closer look.
Faro builds AI agents that untangle the paperwork sitting between a new drug and a doctor being allowed to prescribe it. Clinical trials generate mountains of structured data, patient records, lab results, protocol documents, all of it needing to be checked, cross referenced, and formatted for regulators. That work used to eat months of a research team’s time before a single new therapy could move to the next phase.
Merck’s venture arm did not write this check for a headline either. Six of the ten largest drug makers already run patient data through Faro’s platform, and that kind of quiet, repeat business is a stronger signal than any press release could be.
Handing pieces of that grind to AI agents does not sound as exciting as a new chatbot or a chip announcement, but it might matter more to more people. Every month shaved off a clinical trial timeline is a month closer for someone waiting on a treatment that does not exist yet.
The real case for AI keeps getting made quietly, inside industries most of us never watch closely. Not in a demo on stage. In the slow, unglamorous parts of medicine that outlast the news cycle.
——
Follow: @Ali Demi
Book your free AI clarity call, NOW!
https://buff.ly/TpWy277
——
Sources:
https://faro.ai/blog/what-our-series-b-means-for-our-customers
https://endpoints.news/exclusive-faro-raises-37m-series-b-to-speed-up-clinical-trials-with-ai/
https://finance.yahoo.com/healthcare/articles/faro-raises-37-3m-series-133500551.html
Repost this. Thanks.
